Amalgamated Bank Lowers Position in Moderna, Inc. (NASDAQ:MRNA)

Amalgamated Bank trimmed its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 64,862 shares of the company’s stock after selling 812 shares during the quarter. Amalgamated Bank’s holdings in Moderna were worth $2,697,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its position in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after acquiring an additional 178,939 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $30.96 on Friday. The stock has a market cap of $11.94 billion, a PE ratio of -3.34 and a beta of 1.59. The stock has a fifty day moving average of $37.30 and a 200 day moving average of $51.12. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Analysts Set New Price Targets

MRNA has been the topic of a number of recent research reports. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a report on Monday, November 18th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Piper Sandler reiterated an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Bank of America cut their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus price target of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.